Skip to main content

MenQuadfi FDA Approval History

Last updated by Judith Stewart, BPharm on June 24, 2020.

FDA Approved: Yes (First approved April 23, 2020)
Brand name: MenQuadfi
Generic name: meningococcal (groups A, C, Y, W) conjugate vaccine
Dosage form: Injection
Company: Sanofi
Treatment for: Meningococcal Disease Prophylaxis

MenQuadfi (meningococcal (groups A, C, Y, W) conjugate vaccine) is a MenACWY vaccine indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 years of age and older.

  • MenQuadfi does not prevent Neisseria meningitidis serogroup B disease.
  • MenQuadfi is administered as an intramuscular injection.
  • In the U.S., the CDC recommends vaccination against meningococcal disease with the MenACWY vaccine at 11-12 years of age with a booster dose at 16 years of age.
  • MenQuadfi should not be given to people who have had a severe allergic reaction after a previous dose of MenQuadfi, any of its ingredients, or another vaccine that contains tetanus toxoid.
  • The most common side effects following a first dose of MenQuadfi included injection site pain (25.5%–45.2%), muscle ache (20.1%–35.6%), headache (12.5%–30.2%), and tiredness (14.5%–26.0%). In adolescents and adults receiving a MenQuadfi booster, similar rates of these reactions were observed.

Development timeline for MenQuadfi

Apr 24, 2020Approval FDA Approves MenQuadfi (Meningococcal (Groups A, C, Y, W) Conjugate Vaccine) for Meningococcal (MenACWY) Vaccination

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.